Moreover,
Komboglyze marketing will cease end:
A judgment decided only due to commercial considerations. Nevertheless, yalcinsonat1 / iStock / Getty Images Plus / via Getty Images
Lhe Astrazeneca laboratory has decided to stop the marketing of Komboglyze dual therapy 2.5 mg/1,000 mg film -coated tablet (saxagliptin, chlorhydrate of metformin – cf. Framed) in France (city and hospital), for commercial reasons [1].
The marketing judgment will be effective from January 30, 2026 on the entire distribution and dispensation circuit.
|
Komboglyze is indicated in adult patients with type 2 diabetes to improve blood sugar control, in addition to a diet and physical activity:
|
The only combination of saxagliptin and metformin – Komboglyze marketing will cease end
Marketed in 2012, Komboglyze is the only specialty combining saxagliptin (2.5 mg) and metformin (1,000 mg).
These two active ingredients remain available separately:
No longer initiate treatment with komboglyze and reassess current treatments
From now on and until the effective marketing stop, the Laboratory and the National Agency for the Safety of Medicines and Health Products (ANSM) invite to anticipate the Komboglyze marketing stop:
- no longer initiate new prescription or Komboglyze renewal;
- Inform patients of Komboglyze’s komboglyze marketing will cease end upcoming unavailability and invite them to consult their doctor;
- Consider an alternative treatment, such as the separate socket of saxagliptin and metformin (taking into account the difference in dosage in saxagliptin between Onglyza and Komboglyze).

.
“When setting up the new therapy, special attention should be paid to the impact of the half-life of the products in order to avoid any risk of under or overdose”advises the laboratory in a letter addressed to prescribers on July 15, 2025 [1].
Further reading: Dyspnea and edema of the lower limbs – The free program for a serene summer – Barbecue: How to avoid health dangers? – What is the best SPF 50 sunscreen to choose in 2025? – Ontario remains the province that is the hardest affected by measles hatching.
